Best Biologic for Rheumatoid Arthritis in 2026
Comparing all FDA-approved RA biologics by mechanism, efficacy, safety, and patient factors
Key Takeaways
- RA biologics span 6 different mechanisms — giving rheumatologists many options after treatment failure
- Rinvoq showed numerically superior ACR response vs Humira in the SELECT-COMPARE trial
- TNF inhibitors (Humira, Enbrel) remain widely used first-line with the longest safety track record
- Orencia and Actemra are preferred options after TNF failure
- Most insured RA patients pay $0–$35/month through manufacturer savings programs
FDA-Approved Biologics for Rheumatoid Arthritis
| Medication | Class | Route | Key Advantage | Copay |
|---|---|---|---|---|
| Rinvoq | JAK1 | Oral daily | Numerically superior ACR response vs Humira (SELECT-COMPARE) | $0–$10/mo |
| Humira | TNF-α | SQ q2wk | Longest track record; biosimilars available; covers many conditions | $0–$35/mo |
| Enbrel | TNF-α | SQ weekly | Long track record; doesn't worsen demyelinating disease as strongly as other TNFs | $0–$10/mo |
| Actemra | IL-6 | SQ or IV | Can be used as monotherapy without MTX; fast CRP normalization | $0–$5/mo |
| Orencia | T-cell | SQ or IV | Preferred after TNF failure; favorable infection profile; safe in COPD | $0–$5/mo |
| Kevzara | IL-6 | SQ q2wk | Strong IL-6 inhibition; good option after TNF failure | $0–$5/mo |
| Xeljanz | JAK1/3 | Oral | Oral option; established; black box warnings limit use in older patients | $0–$5/mo |
| Cimzia | TNF-α | SQ q2wk | Lowest placental transfer — preferred in women of childbearing age | $0–$5/mo |
How Rheumatologists Choose the Right RA Biologic
First biologic (biologic-naive)
TNF inhibitors (Humira, Enbrel, Remicade) or JAK1 inhibitors (Rinvoq) are common first choices. Head-to-head data shows Rinvoq achieved superior ACR50/70 rates vs Humira in SELECT-COMPARE.
After TNF failure
Switch mechanism class. Orencia, Actemra, Kevzara, or a JAK inhibitor are strong options. Rituximab (not covered by BiologicHealthPlus) is also used after TNF failure in seropositive RA.
Infection concerns / older patients
Orencia has a favorable infection profile compared to TNF inhibitors. Entyvio (not RA-approved) analogy: gut-selective agents. For RA, Orencia or lower-dose Actemra may be preferred.
Planning pregnancy
Cimzia (certolizumab) has the lowest placental transfer of any TNF inhibitor and is often preferred for women who may become pregnant. Discuss timing and options with your rheumatologist.
💊 BiologicHealthPlus Carries All RA Biologics
Prior authorization, copay enrollment, and free cold-chain delivery for Rinvoq, Humira, Enbrel, Orencia, Actemra, Kevzara, Xeljanz, Cimzia, Simponi, and Remicade.
RA Treatment Guide →📚 Sources & Further Reading
Content developed with reference to leading health organizations, peer-reviewed research, and FDA prescribing information.
Medical Disclaimer: Educational content reviewed by the BiologicHealthPlus Clinical Team. Consult your healthcare provider for personalized advice. Last reviewed: August 2026.